Products Affected - Description
Testosterone enanthate injection
Reason for the Shortage
- Watson could not provide a reason for the shortage.
- Endo discontinued brand name Delatestryl in 2011.
Testosterone enanthate injection, Watson
200 mg/mL, 5 mL vials (NDC 00591-3221-26)
Testosterone enanthate injection, West-Ward
200 mg/mL, 5 mL vials (NDC 00143-9750-01)
Estimated Resupply Dates
All presentations are available.
August 18, 2014; May 15, 2014; March 27, 2014; January 30, 2014; December 5, 2013; December 4, 2013; November 11, 2013; September 18, 2013; July 30, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins